Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata listed "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended December 31, 2001
Business Overview: The Company provides productivity tools, software, and research services globally to pharmaceutical and biotechnology firms to support drug development. Operations are divided into two segments: analytical services (contract chemistry support) and analytical products (liquid chromatography, electrochemical, and physiological monitoring products).
Key Financial Metrics
| Metric | Q1 2002 (Ended Dec 31, 2001) | Q1 2001 (Ended Dec 31, 2000) |
|---|---|---|
| Total Revenue | $6,023,000 | $5,426,000 |
| Gross Profit | $2,556,000 | $2,422,000 |
| Operating Income | $437,000 | $491,000 |
| Net Income | $247,000 | $195,000 |
| Diluted EPS | $0.05 | $0.04 |
| Cash and Equivalents | $636,000 | $391,000 |
| Operating Cash Flow | $14,000 | ($64,000) |
| Total Debt (Current + Long-term) | $3,859,000 | Filing text does not provide a clear comparative total for Dec 31, 2000 |
| Revolving Line of Credit Utilized | $883,000 | Filing text does not provide a clear comparative value for Dec 31, 2000 |
Margins: Gross margin was approximately 42.4% for the quarter. The effective tax rate was 40.0%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11.0% ($597,000) driven primarily by new contracts in the service group, which grew service revenue from $3.1 million to $3.6 million.
- Cost Structure: Total cost of revenue increased 15.4%. Cost of services rose to 73.4% of service revenue (from 72.4%), and cost of products rose to 34.5% (from 32.7%) due to product mix changes.
- Operating Expenses: General and administrative expenses increased 33.8% to $1.0 million due to organizational restructuring of preclinical operations. Conversely, R&D expenses decreased 18.0% to $323,000 due to increased grant reimbursements.
- Profitability: Despite higher revenue, operating income decreased 11.0% to $437,000 due to increased costs and G&A expenses. However, Net Income increased 26.7% to $247,000, aided by a significant reduction in interest expense and a lower effective tax rate.
- Liquidity: Cash and cash equivalents increased from $374,000 (Sept 30, 2001) to $636,000 (Dec 31, 2001), primarily due to financing activities (increased line of credit utilization).
Outlook, Risks, and Management Commentary
- Capital Expenditures: The Company signed a letter of intent to expand facilities at its Evansville, Indiana preclinical site with a commitment of approximately $2.5 million. Construction is expected to complete in December 2002, financed by a new commercial mortgage.
- Liquidity Position: Management believes cash from operations and the existing $3.5 million revolving line of credit (expiring April 1, 2002) are sufficient to fund working capital and capital expenditure requirements.
- Debt Covenants: The revolving line of credit is collateralized by inventory and accounts receivable and requires maintenance of specific financial ratios. Interest rates are tied to prime or LIBOR.
- Accounting Changes: The Company noted upcoming adoption of SFAS No. 141 and 142 regarding goodwill, expected to increase net income by approximately $77,000 annually starting in fiscal 2003. SFAS No. 144 regarding asset impairment is also noted but not expected to be material.
- Litigation: No material litigation is currently pending.
Investor Verification Checklist
- Verify the sustainability of the 11% revenue growth and whether the increase in cost of revenue (15.4%) is a temporary mix issue or a structural trend.
- Confirm the Company's ability to secure the new commercial mortgage for the $2.5 million Evansville expansion before the current line of credit expires in April 2002.
- Monitor the impact of the organizational restructuring on future General and Administrative expenses.
- Review the specific financial ratios required by the bank to maintain the revolving line of credit and assess the risk of covenant breach.
- Validate the timeline and cost estimates for the Evansville facility expansion to ensure no budget overruns.